Synchronous Mucocutaneous Paracoccidioidomycosis and Oral Squamous Cell Carcinoma: Report of Two Rare Cases.

J Cutan PatholApr 16, 2026 (epub)
Case ReportInfectious DiseasesOncology (Medical)Open access

José Alcides Almeida de Arruda, Giovanna Ferriello, Camila Metzner Tristão et al.

✦ AI-curated · Sources linked

Case in brief

Two men, aged 42 and 48, from Southeast Brazil presented with painful, ulcerated oral lesions characterized by granular features, diagnosed as synchronous mucocutaneous paracoccidioidomycosis (PCM) and oral squamous cell carcinoma (OSCC). Histopathological examination confirmed PCM, and both patients exhibited pulmonary involvement. Treatment with itraconazole was complicated by non-compliance. One patient underwent surgical resection for OSCC, while the other is receiving chemoradiotherapy.

Diagnostic / clinical pearl

Clinicians should be vigilant for the coexistence of oral squamous cell carcinoma with paracoccidioidomycosis, especially in endemic regions, and consider multi-site biopsies for granulomatous oral lesions.

Source

PubMed · PMID 41991326Free full text on PubMed Central

Published in J Cutan Pathol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Infectious Diseases

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.